V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210003635 | 210006933 | 1.68 | 68.9 | Adjuvant (A) | 2016-03-20 | 2016-04-07 | FEC 100 | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101110095 |
| 210003636 | 210006934 | 1.64 | null | Adjuvant (A) | 2018-10-12 | 2019-01-17 | null | null | N | TRIAL UNSPECIFIED | 101841491 |
| 210003640 | 210006937 | null | null | null | null | 2016-09-21 | null | null | null | ROSCO TRIAL | 100230306 |
| 210003641 | 210006938 | 1.63 | 50 | Adjuvant (A) | null | 2019-10-15 | EC | null | N | EC | 100075897 |
| 210003645 | 210006941 | 1.56 | 121.8 | null | 2017-06-06 | 2017-06-25 | Hydroxycarbamide | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL + TRASTUZUMAB | 100213240 |
| 210003646 | 210006942 | 1.58 | 55 | Adjuvant (A) | 2016-06-23 | 2016-06-23 | Palbociclib | null | N | EPIRUBICIN | 100777280 |
| 210003648 | 210006944 | null | 62.5 | null | 2017-10-20 | 2017-11-25 | FEC 100 | null | null | FEC | 100213352 |
| 210003650 | 210006946 | 1.72 | 70.1 | Palliative (P) | null | 2018-10-23 | Fulvestrant + Palbociclib | N | N | ROSCO TRIAL | 101174760 |
| 210003653 | 210006948 | null | null | null | 2017-06-07 | 2017-09-06 | Olaparib | null | null | VINORELBINE | 101719302 |
| 210003654 | 210006949 | 1.67 | 74 | Neo-adjuvant (N) | 2017-07-08 | 2017-10-05 | FEC + DOCETAXEL | 02 | N | FEC + DOCETAXEL | 101430286 |
| 210003656 | 210006951 | 1.69 | 79.1 | null | null | 2018-11-23 | null | null | null | CARBOPLATIN + DOCETAXEL | 101093115 |
| 210003658 | 210006952 | null | 104 | null | null | 2017-09-18 | null | 02 | null | PACLITAXEL + TRASTUZUMAB | 101659177 |
| 210003661 | 210006955 | 1.79 | 63.6 | Adjuvant (A) | 2018-11-20 | 2018-12-05 | EC | 02 | N | EC | 101142984 |
| 210003662 | 210006956 | 1.69 | 97 | Palliative (P) | 2017-03-01 | 2017-03-02 | FEC + DOCETAXEL | 02 | N | FEC + DOCETAXEL | 100138986 |
| 210003663 | 210006957 | null | 0 | null | 2017-11-20 | 2018-01-22 | EC | null | null | EC | 100137596 |
| 210003668 | 210006961 | null | null | null | null | 2020-08-23 | FEC + DOCETAXEL | N | null | FEC + DOCETAXEL | 100079302 |
| 210003675 | 210006965 | 1.58 | 62.45 | Palliative (P) | 2016-11-30 | 2016-11-30 | null | null | N | CAPECITABINE | 100967742 |
| 210003677 | 210006967 | null | null | null | 2019-04-23 | 2019-05-30 | Paclitaxel albumin (Abraxane) 21day | null | null | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 101174176 |
| 210003678 | 210006968 | 1.64 | 69 | Adjuvant (A) | 2014-06-12 | 2014-06-19 | null | N | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 100035580 |
| 210003681 | 210006970 | 0 | 86 | null | 2019-12-12 | 2019-12-17 | SACITUZUMAB GOVITECAN | 02 | null | CARBOPLATIN + DOCETAXEL | 101205386 |
| 210003682 | 210006971 | 1.69 | 71.5 | null | 2016-03-25 | 2016-04-02 | FEC 100 | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101717317 |
| 210003685 | 210006973 | 1.63 | 62 | null | 2016-11-09 | 2016-11-24 | FEC 100 | N | null | FEC | 100167590 |
| 210003690 | 210006976 | 1.58 | 70.75 | null | null | 2017-12-28 | TRASTUZUMAB DERUXTECAN | null | null | CAPECITABINE | 100856400 |
| 210003692 | 210006978 | 1.54 | 66 | Palliative (P) | 2018-10-25 | 2018-11-14 | Paclitaxel+Trastuzumab wkly Maint | null | N | PACLITAXEL + TRASTUZUMAB | 100423329 |
| 210003693 | 210006979 | null | null | null | 2018-01-08 | 2018-02-07 | EC + PACLITAXEL | null | null | CISPLATIN + ETOPOSIDE | 100959064 |
| 210003697 | 210006980 | 1.78 | 0 | null | null | 2017-10-19 | FEC + DOCETAXEL | 02 | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100712049 |
| 210003698 | 210006981 | null | 72 | null | 2020-08-15 | 2020-08-22 | GemCarbo Days 1+8 | 02 | null | CONCEPT TRIAL | 100105527 |
| 210003703 | 210006985 | 1.56 | 58 | Palliative (P) | null | 2018-07-27 | FEC | 02 | N | PALBOCICLIB | 101702403 |
| 210003704 | 210006986 | 1.53 | 56 | null | 2018-08-26 | 2018-08-27 | null | 02 | null | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100268655 |
| 210003705 | 210006987 | 1.66 | 55.3 | 03 | 2017-06-18 | 2017-07-03 | EC | 02 | N | EC | 100776863 |
| 210003707 | 210006989 | 1.58 | 81.7 | Adjuvant (A) | 2017-02-08 | 2017-02-25 | FEC 100 | N | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101126331 |
| 210003708 | 210006990 | null | null | null | 2018-02-23 | 2018-03-13 | FEC + DOCETAXEL | N | null | FEC + DOCETAXEL | 100216756 |
| 210003711 | 210006992 | null | null | null | 2016-05-28 | 2016-06-14 | FEC + DOCETAXEL | 02 | null | FEC + DOCETAXEL | 101335670 |
| 210003712 | 210006993 | 1.72 | 77.4 | null | 2017-04-29 | 2017-05-15 | FEC 60 or 75 | 02 | null | FEC | 101840371 |
| 210003713 | 210006994 | 1.48 | null | Neo-adjuvant (N) | 2018-10-20 | 2019-01-24 | Doce + Pertuzumab + Trastuz IV Load | null | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100129323 |
| 210003717 | 210006998 | 1.61 | 57.7 | Neo-adjuvant (N) | 2016-02-01 | 2016-02-15 | null | null | N | ATEZOLIZUMAB + NAB-PACLITAXEL | 100417507 |
| 210003719 | 210006999 | 1.55 | 78.5 | Palliative (P) | null | 2018-05-11 | Paclitaxel+Trastuzumab wkly Maint | null | N | PACLITAXEL + TRASTUZUMAB | 101426308 |
| 210003721 | 210007001 | 1.71 | 90 | Neo-adjuvant (N) | 2016-08-01 | 2019-03-02 | null | 02 | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 100577965 |
| 210003722 | 210007002 | 1.61 | 82 | Adjuvant (A) | 2016-10-09 | 2016-10-29 | FEC 60 or 75 | 02 | N | FEC | 100420307 |
| 210003723 | 210007003 | 0 | null | Neo-adjuvant (N) | 2018-08-17 | 2018-09-08 | FEC + DOCETAXEL | N | Y | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100832036 |
| 210003724 | 210007004 | 1.65 | 70.4 | null | 2019-04-21 | 2019-05-03 | Trial Unspecified | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL | 100138044 |
| 210003725 | 210007005 | 1.7 | 99 | Palliative (P) | 2016-10-27 | 2016-11-03 | Paclitaxel+Trastuzumab wkly Maint | null | N | PACLITAXEL + TRASTUZUMAB | 100388097 |
| 210003727 | 210007006 | null | 56.6 | null | 2016-08-05 | 2016-08-18 | FEC 60 or 75 | null | null | FEC | 101141121 |
| 210003728 | 210007007 | 1.59 | 65.7 | Palliative (P) | 2017-05-30 | 2017-06-01 | null | null | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100605706 |
| 210003729 | 210007008 | 1.68 | 93.45 | null | 2018-03-26 | 2018-04-04 | FEC 100 | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100347717 |
| 210003731 | 210007009 | 1.68 | 71.3 | Adjuvant (A) | null | 2016-10-28 | null | 2 | N | ATEZOLIZUMAB + NAB-PACLITAXEL | 100516254 |
| 210003736 | 210007012 | null | 80 | null | 2018-09-22 | 2018-10-11 | EC | 02 | null | EC | 101855705 |
| 210003738 | 210007013 | 1.58 | 64.85 | Neo-adjuvant (N) | 2018-08-29 | 2018-09-23 | null | null | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100565820 |
| 210003743 | 210007018 | null | null | null | null | 2019-01-11 | Trial Unspecified | 02 | null | EVEROLIMUS | 100196066 |
| 210003744 | 210007019 | 1.51 | 75.2 | Adjuvant (A) | 2017-02-06 | 2017-02-17 | FEC + DOCETAXEL | N | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 101097585 |